Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY21 89102, a neutralizing IL-1β antibody, in patients with type 2 diabetes

Authors :: Sloan-Lancaster, Joanne
Abu-Raddad, Eyas
Polzer, John
Miller, Jeffrey W.
Scherer, Joel C.
De Gaetano, Andrea
Berg, Jolene K.
Landschulz, William H.
Source :: Diabetes Care. August 1, 2013, Vol. 36 Issue 8, p2239, 8 p.
Publication Year :: 2013
Abstract: OBJECTIVE--Inflammation is associated with pancreatic β-cell apoptosis and reduced insulin sensitivity. Literature suggests that interleukin (IL)-1β may contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). This study aimed [...]

Subjects :: European Association for the Study of Diabetes
Care and treatment
Analysis
Development and progression
Apoptosis -- Analysis
Interleukins -- Analysis
Anti-inflammatory agents -- Analysis
Hypoglycemic agents -- Analysis
Type 2 diabetes -- Development and progression -- Care and treatment -- Analysis
Cholesterol -- Analysis
Antibodies -- Analysis
Viral antibodies -- Analysis
Anti-inflammatory drugs -- Analysis

Full Text Access

Tools